Method of treating dyslipidemic disorder

Details Method of treating dyslipidemic disorder Method of treating dyslipidemic disorder

2011-08-09

2011-08-09

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C530S350000, C424S009100

Reexamination Certificate

active

07994120

ABSTRACT:
The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.

REFERENCES:
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6037323 (2000-03-01), Dasseux et al.
patent: 6046166 (2000-04-01), Dasseux et al.
patent: 6258596 (2001-07-01), Benoit et al.
patent: 6265377 (2001-07-01), Dasseux et al.
patent: 6329341 (2001-12-01), Dasseux et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 7435717 (2008-10-01), Bisgaier et al.
patent: 59-278140 (1984-12-01), None
patent: 61152632 (1986-07-01), None
patent: WO 93/12143 (1993-06-01), None
patent: WO 93/25581 (1993-12-01), None
patent: WO 94/13819 (1994-06-01), None
patent: WO 96/04916 (1996-02-01), None
patent: WO 96/05227 (1996-02-01), None
patent: WO 96/37608 (1996-11-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 97/43311 (1997-11-01), None
patent: 9916459 (1999-04-01), None
patent: 0158492 (2001-08-01), None
patent: WO 02/30359 (2002-04-01), None
patent: PCT/US03/015469 (2003-09-01), None
Ameli, S., et al., “Recombinant Apolipoprotein A-I Milano Reduces Intimal Thickening After Balloon Injury In Hypercholesterolemic Rabbits,” (1994),Circulation, 90(4), pp. 1935-1941.
Aviram, M., et el., “Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group And Is Different From That Required For Its Arylesterase/Paraoxonase Activities: Selective Action Of Human Paraoxonase Allozymes Q And R,” (1998),Arterioscler. Thromb. Vasc. Biol., 18, pp. 1617-1624.
Aviram. M., et al, “Paramonase Inhibits High-Dcnsity Lipoprotein Oxidation and Preserves Its Functions: A Possible Peroxidative Role For Paraoxonase,” (1998),J. Clin. Invest., 101, pp. 1581-1590.
Badimon, I.J., et al., “Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit,” (1990),J. Clin. Invest., 85, pp. 1234-1241.
Beitz, J., et al, “Does a HDL Injection Reduce the Development of Serum Hyperlipidemia and Progression of Fatty Streaks in Cholesterol Fed Rabbits?” (1992),Prostoglandins Leukotrienes and Essential Fatty Acids, 47, pp. 149-152.
Berard, A.M., et al., “High Plasma HDL Concentrations Associated with Enhanced Atherosclerosis in Transgenic Mice Overexpressing Lecithin-Cholesteryl Acyltransferase,” (1997).Nat. Med., 3(7), pp. 744-749.
Billecke, S., et et, “Human Serum Paraoxonase (PON1) Isozymes Q And R Hydrolyze Lactones And Cyclic Carbonate Esters,” (2000)Drug Metab. Dispos., 28, pp. 1335-1342.
Carlson, L.A., “Effect of a Single Infusion of Recombinant Human Proapolipoprotein A-I Liposomes (Synthetic HDL) on Plasma Lipoproteins in Patients with Low High Density Lipoprotein Cholesterol,” (1995)Nutr. Metab. Cardiovas. Dis., 5, pp. 85-91.
Cheung, M.C., et al, “Altered Particle Size Distribution of Apolipoprotein A-I-Containing Lipoproteins in Subjects with Coronary Artery Disease,”(1991),J. Lipid Res., 32, pp. 383-394.
Corijn, J., et al., “Synthetic Model Peptides for Apolipoproteins. II. Characterization of the Discoidal Complexes Generated Between Phospholipids and Synthetic model Peptides for Apolipoproteins,” (1993).Biochim. Biophys. Acta, 1170, pp. 8-16.
Dragonov, D.I., et al., “Rabbit Scrum Paraoxonase 3 (PON3) is A High Density Lipoprotein-Associated Lactonase and Protects Low Density Lipoprotein Against Oxidation,” (2000),J. Biol. Chem., 275 (43), 33435-33442.
Duverger, N., et al., “Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-1-Transgenic Rabbits,” (1996),Circulation, 994(4), pp. 713-717.
Dyer, C.A.,et al., “Only Multimers Of A Synthetic Peptide Of Human Apolipoprotein E Are Biologically Active,” (1991),J. Biol. Chem., 266(23), pp. 15009-15015.
Dyer, C.A., et al., “Structural Features of Synthetic Peptides of Apolipoprotein E Bind the LDI Receptor,” (1995),J. Lipid. Res., 36, pp. 80-88.
Emmanuel, F.,et al. “Identification of Specific Amphipathic α-Helical Sequence of Human Apolipoprotein A-IV Involved In Lecithin: Cholesterol Acyltransferase Activation,” (1994),J. Biol. Chem., 269(47), pp. 29883-29890.
Fournier, N., et al., “Role of HDL Phospholipid in Efflux of Cell Cholesterol to Whole Serum: Studies with Human apoA-1 Transgenic Rats,” (1996)J. Lipid Res., 37, pp. 1704-1711.
Franceschini, G., et al., “A-IMILANOApoprotein: Decreased High Density Lipoprotein Cholesterol Levels With Significant Lipoprotein Modifications and Without Clinical Atherosclerosis in an Italian Family,” (1980),J. Clin. Invest., 66, pp. 892-900.
Franceschini, G., et al., “Apolipoprotein A-IMILANO: Correlation Between High Density Lipoprotein Subclass Distribution and Triglyceridemia,” (1987),Arteriosclerosis, 7, pp. 426-435.
Franceschini, G., et al., “Apolipoprotein AI-Milano: Altered Lipid Binding Properties In A Human Apolipoprotein Variant,”Recent Aspects of Diagnals and Treatnient of Lipoprotein Disorders Impact on Prevention of Atherosclerotic Diseases, (1986), pp. 73-80.
Francesehini, G., et al., “Relation Between the HDL Apoproteins and AI Isoproteins In Subjects With the AIMILANOAbnormality,” (1981),Metabolism, 30(5), pp. 502-509.
Francone, O.L., et al., “Expression of Human Lecithin-Cholesterol Acyltransferase in Transgenic Mice: Effect of Human Apolipoprotein AI and Human Apolipoprotein AII on Plasma Lipoprotein Cholesterol Metabolism,” (1995),J. Clin. Invest., 96, pp. 1440-1448.
Gordon, D.J., et al., “High-Density Lipoprotein-The Clinical Implications of Recent Studies,” (1989),N. Eng. J. Med., 321, pp. 1311-1316.
Gordon, D.J., et al., “High-Density Lipoprotein Cholesterol and Cardiovascular Disease: Four Prospective American Studies”, (1989),Circulation, 79(1), pp. 8-15.
Gordon, J.I., et al., “Biosynthesis Of Human Preapolipoprotein A-IV,” (1984),J. Biol. Chem., 259(1), pp. 468-474.
Gualandri, N., et al., “AIMilanoApoprotein Identification of the Complete Kindred and Evidence of a Dominant Genetic Transmission,” (1985),Am. J..Hum. Genet., 37, pp. 1083-1097.
Hoeg, J.M., et al., “Human Apolipoprotein A-I: Post-Translational Modification By Fatty Acid Acylation,” (1986),J. Biol. Chem., 261(9), pp. 3911-3914.
Holvoet, P., et al., “Phospholipid Binding and Lechithin-Cholesterol Acyltransferase Activation Properties of Apolipoprotein A-I Mutants,” (1995),Biochem., 34, pp. 13334-13342.
James, R.W., et al., “Modulated Serum Activities and Concentrations of Paraoxonase in High Density Lipoprotein Deficiency States,” (1998),Atherosclerosis, 139, pp. 77-82.
Koizumi, J., et al., “Behavior of Human Apolipoprotein A-I: Phospholipid and apoHDL phospolipid Complexes in Vitro and After Injection into Rabbits”, (1988),J. Lipid. Res., 29, pp. 1405-1415.
Lackner, K.I, “Isoforms Of Apolipoprotein A-II In Human Plasma And Thoracic Duct Lymph: Identification Of Proapolipoprotein A-II and Sialic Acid-Containing Isoforms,” (1985),J. Biol. Chem., 260(2), pp. 703-706.
Li, D., et al., “Inhibition of Arterial Thrombus Formation by ApoAI Milano,” (1999),Arterioscler. Thromb. Vasc. Biol., 19, pp. 378-383.
Lin, A.C., et al., “Human Apolipoprotein A-I Prevents Atherosclerosis Associated with Apolipoprotein[a] in Transgenic Mice,” (1994),J. Lipid Res., 35, pp. 2263-2267.
Lund-Katz, S., et al., “Nuclear Magnetic Resonance Investigation of the Interations with Phospholipid of an Amphipathic or Helix-Forming Peptide of the Apolipoprotein Class,” (1990),J. Biol. Chem., 265(21), pp. 12217-12223.
Mezdour, H., et al., 

Affiliated with

Also associated with

Rating

Method of treating dyslipidemic disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating dyslipidemic disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dyslipidemic disorder will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2766175